1. Scrip
  2. >>Business
  3. >>Deals

Start-Up Quarterly Statistics, Q4 2013

 
• By Deanna Kamienski

Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.

In the fourth quarter of 2013, start-up companies raised an aggregate of $1.18 billion, more than double Q3’s $559.4 million. That total is the highest we’ve seen since START-UP began featuring this column exactly five years ago; 89% ($1.04 billion) was attributed to biopharma fundraising, half of which was from Series A rounds. (Q4 2011’s $692.9 million was the second-highest total in the biopharmaceutical sector.) Medical device firms generated $11 million more than last quarter with $54 million, while four in vitro diagnostic start-ups raised a combined $81 million. (See Exhibit 1.)

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

More from Business

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By Manas Mishra

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Amgen Plans AI Investment Amid Strong Sales Growth

 
• By Alaric DeArment

CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.